SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Promoting the value of discipline and how it can help to improve everyone’s life. Whether it may be with fitness, quitting bad habits such as smoking, learning a new skill such as trading. We are helping people to learn how important it is to have discipline and how that can help them to succeed as it is needed to make the dream a reality, helping people to setup their rules in order to achieve what they are really going for.

DISCIPLINE

DISCIPLINE is trending as the community discusses its availability on Phantom Wallet and potential integration within the Solana ecosystem. Bullish sentiment is met with skepticism, as some users warn of potential pump-and-dump schemes, while others highlight the project's growth.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending amid community excitement surrounding its real-world applications, including KENDU energy drinks, beers, and community-driven businesses. The community is actively promoting the new website and highlighting the growing number of holders, suggesting increasing adoption. Discussions emphasize the project's strong community, IRL presence, and long-term vision, solidifying its reputation as a promising brand coin.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to a recently announced record-breaking hospital contract and its regained NASDAQ compliance, sparking discussions of a potential short squeeze. The stock's low float and high cost to borrow are attracting attention, with traders comparing it to other Hong Kong-based stocks that have recently experienced significant gains. Community members are actively monitoring the stock, anticipating an explosive move.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

$LEU is trending as community members discuss its strong financial position, including net cash positivity and growing income. Bullish sentiment is fueled by high profit margins and significant short interest, potentially setting up a short squeeze. Some traders are drawing comparisons to other energy plays and anticipating a further run, while also pointing to sector rule where other nuclear stocks can move together.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

MFI is trending due to speculation around potential crypto-related developments and a low float, leading to discussions of a possible short squeeze. Community members are closely watching for news catalysts, especially concerning a potential crypto exchange partnership and expansion into mainland China. Some traders are drawing comparisons to other low-float stocks that have experienced significant price increases, contributing to the heightened interest.

PAX Gold (PAXG) is an asset-backed token where one token should represent one fine troy ounce of a London Good Delivery gold bar, stored in professional vault facilities. Anyone who owns PAXG has ownership rights to that gold under the custody of Paxos Trust Company. Since PAXG represents physical gold, its value is tied directly to the real-time market value of that physical gold.  PAXG gives customers the benefits of actual physical ownership of specific gold bars with the speed and mobility of a digital asset. Customers are able to have fractional ownership of physical bars. On the Paxos platform, customers can convert their tokens to allocated gold, unallocated gold, or fiat currency (and vice versa) quickly and efficiently, reducing their exposure to settlement risk. PAXG is also available for trading on Paxos’ itBit exchange. PAXG will also be available on other crypto-asset exchanges, wallets, lending platforms and elsewhere within the crypto ecosystem.   At any time, PAXG holders can lookup the serial number, value and physical characteristics of their vaulted gold just by entering their Ethereum wallet address on the PAXG lookup tool on Paxos.com/paxgold.

PAX Gold

PAX Gold is trending as community members discuss its potential as a safe haven asset, especially amidst broader market uncertainty and crypto sell-offs; some see it as a compelling alternative to Bitcoin. Community members are also comparing it to other gold-backed tokens and considering it as a hedge against traditional financial systems. Recent news around Paxos and licenses may also be contributing to the interest.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is experiencing heightened chatter as the price tests resistance levels, sparking debate about a potential breakout or breakdown. Community members are actively discussing short squeezes and longing for a move back into the $40s, while some express concerns about low volume and governance issues.

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Idexx Laboratories, Inc.

IDXX is trending due to unusual options activity and upgrades from analysts, although one analyst lowered their price target. The community is closely monitoring call options activity, seemingly expressing bullish sentiment, and analyzing the company's growth prospects in the veterinary diagnostics market. Some are also citing the potential for a merger with Zomedica.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley is trending as community members discuss the potential impact of evolving market conditions on the financial sector. Traders are analyzing technical indicators and catalysts while assessing the company's growth opportunities amid broader economic uncertainty and potential M&A activity. News of analyst ratings adjustments and increased institutional ownership is also fueling conversation.

Exelon Corp. is a utility services holding company, which engages in the energy distribution and transmission businesses. It operates through the following segments: Commonwealth Edison Company, PECO Energy Company, Baltimore Gas and Electric Company, Potomac Electric Power Company, Delmarva Power and Light Company, and Atlantic City Electric Company. The company was founded on February 4, 1999 and is headquartered in Chicago, IL.

Exelon Corp.

Exelon is trending due to a mix of factors, including analysts adjusting price targets and ratings, and a focus on the company's role in the energy transition. Community discussion highlights potential investment opportunities amid infrastructure developments and a commitment to diversity, equity, and inclusion. Investors are also monitoring Exelon's earnings and dividend payouts in the context of increasing data center energy demands and grid modernization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the iShares Biotechnology ETF (IBB)?

Health and Human Services Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee on Sept. 4 to discuss U.S. President Donald Trump’s healthcare agenda.Chairman Mike Crapo said the hearing will focus on “the Department of Health and Human Services’ Make America Healthy Again actions to date and plans moving forward,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/kennedy-testify-before-senate-panel-health-agenda-2025-08-28/">reported</a>.The session comes after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cdc-chief-susan-monarez-pushed-out-after-weeks-on-job-as-rfk-jr-overhauls-agency-she-s-fighting-back/chsCsP4Rdli">White House dismissed CDC Director Susan Monarez</a> on Wednesday, less than a month into her tenure. An associate said Monarez was fired after resisting vaccine policy changes advanced by Kennedy that she believed contradicted scientific evidence.&nbsp;Hours later, three senior officials — Chief Medical Officer Debra Houry, National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan — resigned and were&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/fired-cdc-director-clashed-with-kennedy-on-vaccine-policy-2025-08-28/">reportedly</a> escorted from the Atlanta campus.&nbsp;CDC staff, many wearing green shirts and ribbons as a sign of support, applauded them as they departed.Richard Besser, former acting CDC director, said Monarez told him she would not take any action that was illegal or “flew in the face of science,” and she refused to dismiss her leadership team without cause.&nbsp;The three departing officials said they resigned over anti-vaccine policies and misinformation promoted by Kennedy and his team. Daskalakis said, “I’m a doctor. I took the Hippocratic oath that said, ‘First, do no harm.’ I believe harm is going to happen, and so I can’t be a part of it.”Since taking office this year, Kennedy has fired the CDC’s vaccine advisory panel and replaced it with anti-vaccine activists and other advisers.&nbsp;He has made false claims about vaccines and launched an investigation into autism rates that he has linked, without evidence, to “environmental toxins.”&nbsp;The CDC has since dropped its recommendation that pregnant women be vaccinated against COVID and narrowed its guidance for children with health complications.White House spokeswoman Karoline Leavitt said Monarez was dismissed because she did not align with the president’s mission. “She said she would [resign], and then she said she wouldn’t, so the president fired her,” Leavitt said.&nbsp;Kennedy declined to comment on the specifics of the departures but told&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.foxnews.com/media/rfk-jr-warns-cdc-in-trouble-promises-fixes-director-refuses-step-down">Fox News</a>, “The agency is in trouble, and we need to fix it and we are fixing it. And it may be that some people should not be working there anymore.”&nbsp;Deputy HHS Secretary Jim O’Neill was named interim director of the CDC.Monarez’s dismissal is one of several recent moves by Trump to remove Senate-confirmed officials, including Federal Reserve Governor Lisa Cook and Surface Transportation Board member Robert Primus.On Stocktwits, retail sentiment was ‘bearish’ with ‘low’ message volume for both the iShares Biotechnology ETF (IBB) and the Health Care Select Sector SPDR Fund (XLV).While&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has been flat so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has risen 4.6% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during a cabinet meeting with U.S. President Donald Trump on August 26, 2025 in Washington, DC. (Photo by Chip Somodevilla/Getty Images)

CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit

The White House's move to oust Susan Monarez and the wave of senior CDC resignations have spotlighted deep divisions over vaccine policy and raised fresh questions about the administration’s healthcare agenda.

Equity

U.S. Centers for Disease Control and Prevention Director Susan Monarez has left the agency less than a month after being sworn in, amid the resignation of four senior officials&nbsp;who also resigned over vaccine policy tensions.Monarez’s attorneys said she is challenging her ouster, accusing HHS Secretary Robert F. Kennedy Jr. of targeting her for rejecting “unscientific directives,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-chief-exits-after-weeks-role-three-top-officials-resign-2025-08-27/">reported</a>.&nbsp;“Dr. Monarez has neither resigned nor received notification from the White House that she has been fired, and as a person of integrity and devoted to science, she will not resign,” lawyers Mark S. Zaid and Abbe David Lowell said.The U.S. Department of Health and Human Services' account on X shared a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/HHSGov/status/1960818490614415869">post</a> about Monarez's exit, saying: "We thank her for her dedicated service to the American people. @SecKennedy has full confidence in his team at @CDCgov who will continue to be vigilant in protecting Americans against infectious diseases at home and abroad."CDC Chief Medical Officer Debra Houry and Immunization Center Director Demetre Daskalakis have resigned, citing the rise in health misinformation, attacks on science, and budget cuts.&nbsp;Infectious Diseases Director Daniel Jernigan and Public Health Data Director Jen Layden also stepped down. Houry wrote that overstated risks and misinformation have fueled record measles cases and even a violent attack on the CDC.The White House’s 2026 budget proposed cutting CDC funding by $3.6 billion, while Kennedy had already eliminated 2,400 jobs and rehired 700. Daskalakis said he could not serve amid the “ongoing weaponizing of public health.”The CDC has faced mounting strain under Kennedy, including a shooting at its Atlanta headquarters. Former CDC official Fiona Havers called the latest resignations “devastating,” saying the departed leaders had shielded scientists from political attacks.Kennedy has rolled back vaccine policies, withdrawing COVID shot recommendations for children and pregnant women, and firing all members of the CDC vaccine advisory panel in June, replacing them with hand-picked advisers, including vaccine skeptics.&nbsp;On Wednesday, he announced further changes to COVID-19 vaccine eligibility and stated that autism policy announcements are expected in September.Monarez, a federal scientist, was confirmed on July 29 after being nominated by U.S. President Trump and sworn in by Kennedy on July 31. She succeeded Trump’s withdrawn pick, former congressman and vaccine critic Dave Weldon.&nbsp;On Stocktwits, retail sentiment was bearish for both the iShares Biotechnology ETF (IBB) with normal message volume, and the Health Care Select Sector SPDR Fund (XLV) with low message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has gained 4.9%, while&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has increased by 0.4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monarez is a health scientist with a Ph.D. in microbiology and immunology who previously served as the Deputy Director of the Advanced Research Projects Agency for Health. (Photo by Kayla Bartkowski/Getty Images)

CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back

The sudden leadership shake-up at the CDC deepens turmoil inside the agency, where multiple senior officials have also resigned over vaccine policy disputes with Health Secretary Robert F. Kennedy Jr.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient deaths involving the treatment.&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://stockwits.com/symbol/SRPT">Sarepta’s stock</a> plummeted more than 26% in midday trade on Friday. However, on Stocktwits, retail sentiment around the company remained in ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter.A separate&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-request-sarepta-stop-all-shipments-gene-therapy-elevidys-source-says-2025-07-18/#:~:text=The%20FDA's%20request%20follows%20the,condition%20called%20Duchenne%20muscular%20dystrophy.">report</a> by Reuters said that the FDA plans to request Sarepta to stop all shipments of Elevidys voluntarily.Makary’s comments during an&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/fda-is-investigating-if-sarepta-s-elevidys-should-stay-on-market">interview</a> with Bloomberg come after the company on Thursday disclosed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">third patient death</a> in a clinical trial involving a different experimental gene therapy that uses a similar viral delivery system.&nbsp;A company spokesperson&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.The FDA had already been investigating two earlier deaths linked to Elevidys.The growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for gene treatments that use adeno-associated viral (AAV) vectors. Elevidys, which was granted accelerated approval in 2023 for Duchenne muscular dystrophy, has remained on the market under post-approval study requirements.Bloomberg also reported that the latest death resulted in an unusually tense exchange between analysts and Sarepta executives on a Friday call. The same group of analysts reportedly had a call with the company earlier this week about the future of Elevidys, but the firm failed to disclose the third patient death. On Friday, two of the analysts asked executives whether the company was keeping any other fatalities undisclosed.“We are historically a very transparent organization,” said Sarepta CEO Douglas Ingram, according to the report, adding that the company didn’t disclose the third patient death earlier because “it was neither material nor central” to what was being discussed.&nbsp;Sarepta’s stock is down 88% year-to-date and nearly 90% over the past 12 months.Get updates to this developing story directly on Stocktwits.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grubhub-owner-wonder-reportedly-in-talks-for-500-m-debt-refinancing/ch8kHoKR5qp">Grubhub Owner Wonder Reportedly In Talks For $500M Debt Refinancing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market

The FDA had already been investigating two earlier deaths linked to Elevidys.

Should You Invest in the VanEck Biotech ETF (BBH)?

The U.S. Supreme Court on Friday reportedly preserved a part of the Affordable Care Act (ACA) that helps guarantee that health insurers cover preventive care at no cost to patients.This includes preventive services such as cancer screenings and HIV prevention drugs.The 6-3 ruling was made in a lawsuit over how the government decides which healthcare medications and services are covered by private insurance under the Act commonly referred to as Obamacare, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">reported</a>.The plaintiffs alleged that the process is unconstitutional because the board of 16 medical experts tasked with recommending which services are covered, known as the United States Preventive Services Task Force, is not approved by the Senate but selected by the U.S. Secretary of Health and Human Services.A lower court had ruled in 2024 that the arrangement violated the U.S. Constitution's provision on the appointment of governmental officers, as put forth by the plaintiffs including Christian employers and Texas residents. An appeal was filed by the U.S. government, initially by Democratic former President Joe Biden's administration before being taken up by Republican President Donald Trump's administration.The plaintiffs had included a religious objection to being required to cover pre-exposure prophylaxis for HIV before the case was narrowed to the appointment of the task force. They claimed that the drugs "facilitate and encourage homosexual behavior, prostitution, sexual promiscuity and intravenous drug use."If the Supreme Court justices upheld the lower court’s ruling, life-saving tests and treatments that have been cost-free under most insurance plans may become subject to co-pays and deductibles, public health advocates had warned, the report said.Medications and services that could have been affected include statins to lower cholesterol, lung cancer screenings, HIV-prevention drugs, and medication to lower the chance of breast cancer for women, as <a target="_blank" rel="noopener noreferrer nofollow" href="https://apnews.com/article/supreme-court-obamacare-preventive-care-health-care-d81aa3b66b94642dceafb3e51be9a319">per</a> Associated Press.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/turnstone-biologics-to-merge-with-biotech-royalty-aggregator-xoma/chmg6ZvRRIz">Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Obamacare logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

US Supreme Court Reportedly Upholds Part Of Obamacare That Guarantees Health Insurers Cover Preventive Care

The Obamacare law requires health insurers to provide preventive care, including cancer screenings and HIV prevention medication, at no cost to patients. 

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

BlackRock Institutional Trust Company N.A. - iShares Biotechnology ETF

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$154.19
Prev Close	$153.42
Open	$152.91
Dividend Yield	N/A
50-Day Moving Average	$142.81
Beta	N/A
Avg. Volume	2.01M
PE Ratio	N/A

52-Week High	$156.36
52-Week Low	$107.43
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBB News

IBBiShares Biotechnology ETF